Companhia Siderurgica Nacional (SID) is a leading integrated steel producer in Brazil, playing a vital role in the Latin American steel industry. The company offers a diverse portfolio of high-quality steel products, including flat and long steel, catering to industries such as construction, automotive, and manufacturing. With a strong focus on innovation and sustainability, SID is dedicated to enhancing operational efficiency while reducing its environmental impact. Its significant production capacity and strategic growth initiatives equip SID to capitalize on the increasing global demand for steel, thereby reinforcing its competitive positioning in the market.
| Revenue (TTM) | $45.11B |
| Gross Profit (TTM) | $12.86B |
| EBITDA | $7.21B |
| Operating Margin | 5.54% |
| Return on Equity | -11.70% |
| Return on Assets | 1.96% |
| Revenue/Share (TTM) | $34.02 |
| Book Value | $1.90 |
| Price-to-Book | 0.44 |
| Price-to-Sales (TTM) | 0.03 |
| EV/Revenue | 1.036 |
| EV/EBITDA | 7.11 |
| Quarterly Earnings Growth (YoY) | 3321.00% |
| Quarterly Revenue Growth (YoY) | 5.70% |
| Shares Outstanding | $1.33B |
| Float | $624.76M |
| % Insiders | 0.00% |
| % Institutions | 2.31% |
Volatility is currently contracting
National Steel's Q2 loss misses estimates despite higher revenues, as stronger steel, energy and cement results are offset by financial costs.
National Steel NYSE: SID, also known as CSN, reported higher consolidated EBITDA in the second quarter of 2026, supported by improved commercial performance across its steel, cement, logistics and energy businesses, while management continued to emphasize asset sales, working-capital reductions and debt-management initiatives.
São Paulo, July 30, 2026 (GLOBE NEWSWIRE) -- Companhia Siderúrgica Nacional (“CSN”) (NYSE: SID) announced today that its subsidiary, CSN Inova Ventures (formerly CSN Islands XI Corp.) (the “Issuer”), an exempted company incorporated under the laws of the Cayman Islands and a direct wholly-owned subsidiary of CSN, has commenced an offer to exchange (the “Exchange Offer”) any and all of its outstanding 6.750% Senior Notes due 2028 (the “2028 Notes”) held by Eligible Holders, as defined below, for the Issuer's 11.000% Senior Notes due 2030 (the “New Notes”) and cash. The 2028 Notes are fully, unconditionally and irrevocably guaranteed by CSN.
Companhia Siderúrgica Nacional (SID) faces mounting financial stress as organic deleveraging failed and cash burn persisted over four consecutive quarters. SID's reliance on asset sales, notably its cement unit, has become urgent, with proceeds delayed and bridge loans highlighting liquidity pressures. Despite trading at just 0.15x sales and at a 36% discount to the sector on EV/EBITDA, I now see SID as a potential value trap.
SID incurs a loss in Q1 as softer steel demand, imports and weather drag revenues, though EBITDA rises and margins improve.
National Steel NYSE: SID, the Brazilian steelmaker known as CSN, reported higher first-quarter 2026 adjusted EBITDA despite heavy rainfall, a stronger Brazilian real and continued pressure from steel imports in the early part of the year, executives said on the company's earnings call.
New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy Immunologic markers consistent with soquelitinib's novel mechanism of action and clinical results SID data included in late-breaking oral presentation; company to review data at investor and analyst meeting today at 1:30 pm ET (12:30 pm CT) SOUTH SAN FRANCISCO, Calif.
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the presentation of Phase 2 clinical data highlighting the potential abscopal effects of the Company's novel oncolytic peptide, VP-315 (ruxotemitide), in the treatment of basal cell carcinoma (BCC) at the 2026 Society for Investigative Dermatology (SID) Annual Meeting, taking place from May 13-16, 2026, in Chicago, Illinois.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SID and any ticker you trade — then tracks every position and per-strategy win rate.
